Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Application

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term: pharmacology

<< < Results 501 - 600 of 662 > >>
EC Number Recommended Name Application Commentary
Display the word mapDisplay the reaction diagram Show all sequences 3.5.1.104peptidoglycan-N-acetylglucosamine deacetylase pharmacology studies on peptidoglycan modifications by Streptococcus pneumoniae
Show all pathways known for 3.5.1.108Display the word mapDisplay the reaction diagram Show all sequences 3.5.1.108UDP-3-O-acyl-N-acetylglucosamine deacetylase pharmacology the enzyme is a target for antibiotic therapy and structure-based drug design
Display the word mapDisplay the reaction diagram Show all sequences 3.5.1.119Pup amidohydrolase pharmacology the enzyme provides an ideal target for the development of selective chemotherapies
Display the word mapDisplay the reaction diagram Show all sequences 3.5.2.6beta-lactamase pharmacology enzyme is a target for design of non-beta-lactam, broad-spectrum peptidomimetic enzyme inhibitors
Show all pathways known for 3.5.3.1Display the word mapDisplay the reaction diagram Show all sequences 3.5.3.1arginase pharmacology enzyme is a target for inhibitor design based on arginine analogues with uncharged, tetrahedral functional groups
Show all pathways known for 3.5.3.4Display the word mapDisplay the reaction diagram Show all sequences 3.5.3.4allantoicase pharmacology possibility to develop metabolism-based strategies for mosquito control
Show all pathways known for 3.5.3.6Display the word mapDisplay the reaction diagram Show all sequences 3.5.3.6arginine deiminase pharmacology ADI has anti-cancer activity by causing depletion of L-arginine, fusion of ADI to 20 kDa PEG improves its pharmaceutical efficiency by increasing the half-life of the enzyme in serum, clinical studies, overview
Show all pathways known for 3.5.3.6Display the word mapDisplay the reaction diagram Show all sequences 3.5.3.6arginine deiminase pharmacology ADI is a potential anti-angiogenic agent and is effective in the treatment of leukemia, ADI in clinical studies, overview
Display the word mapDisplay the reaction diagram Show all sequences 3.5.3.15protein-arginine deiminase pharmacology PAD1 is a target in skin diseases including psoriasis
Display the word mapDisplay the reaction diagram Show all sequences 3.5.3.15protein-arginine deiminase pharmacology PAD2 is a target for treatment of glaucoma and multiple sclerosis
Display the word mapDisplay the reaction diagram Show all sequences 3.5.3.15protein-arginine deiminase pharmacology PAD3 is a target in skin diseases including psoriasis, PAD3-like protein is a target for treatment of certain cancers
Display the word mapDisplay the reaction diagram Show all sequences 3.5.3.15protein-arginine deiminase pharmacology PAD4 inhibitors F-and Cl-amidine represent potential lead compounds for the treatment of rheumatoid arthritis because a growing body of evidence supports a role for PAD4 in the onset and progression of this chronic autoimmune disorder
Show all pathways known for 3.5.4.1Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.1cytosine deaminase pharmacology exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy, overview
Show all pathways known for 3.5.4.1Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.1cytosine deaminase pharmacology the recombinant fusion enzyme HSV-1TKglyCD might be useful in cancer gene therapy
Show all pathways known for 3.5.4.1Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.1cytosine deaminase pharmacology applicability of gene-directed enzyme prodrug therapy (GDEPT), prodrug encapsulation in liposomes, liposomal 5-fluorocytosine (5-FC) achieves high local concentration for suicide therapy
Show all pathways known for 3.5.4.1Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.1cytosine deaminase pharmacology applicability of gene-directed enzyme prodrug therapy using the capability of human adipose tissue-derived mesenchymal stem cells (AT-MSC) as cellular vehicles expressing cytosine deaminase, CDy-AT-MSC/5FC-system, analyzed in cell lines and xenografts
Show all pathways known for 3.5.4.1Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.1cytosine deaminase pharmacology applicability of gene-directed enzyme prodrug therapy, feasibility of using magnetic resonance spectroscopy and optical imaging to measure non-invasively expression and function of cytosine deaminase in a preclinical tumor model
Show all pathways known for 3.5.4.1Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.1cytosine deaminase pharmacology cancer chemotherapy, antibody-directed enzyme-prodrug therapy (GDEPT/ADEPT), biopanning assay
Show all pathways known for 3.5.4.1Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.1cytosine deaminase pharmacology negative selection system for actinobacteria based on cytosine deaminase
Show all pathways known for 3.5.4.4Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.4adenosine deaminase pharmacology Plasmodium falciparum-specific inhibitors of adenosine deaminase have potential for development as antimalarials without inhibition of host enzyme
Show all pathways known for 3.5.4.12Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.12dCMP deaminase pharmacology elevated level of dCMPase in transformed cells and tumors: enzyme may represent another important target for cancer chemotherapy
Show all pathways known for 3.5.4.12Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.12dCMP deaminase pharmacology might have applications in cancer chemotherapy. Enzyme may be an inhibitor target for antitumor agents
Show all pathways known for 3.5.4.12Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.12dCMP deaminase pharmacology enzyme might be a reasonable target for chemotherapeutic agents directed against parasitic as well as neoplastic diseases by limiting the synthesis of dUMP, particularly when used in combination with inhibitors of dTMP synthase or other purine and pyrimidine inhibitors of DNA synthesis
Show all pathways known for 3.5.4.25Display the word mapDisplay the reaction diagram Show all sequences 3.5.4.25GTP cyclohydrolase II pharmacology enzyme is a potential drug target, since numerous pathogenic microorganims are absolutely dependent on endogenous synthesis of riboflavin, target for development of bactericidal inhibitors
Show all pathways known for 3.6.1.5Display the word mapDisplay the reaction diagram Show all sequences 3.6.1.5apyrase pharmacology the enzyme may serve as a therapeutic agent for inhibition of platelet-mediated thrombosis
Show all pathways known for 3.6.1.23Display the word mapDisplay the reaction diagram Show all sequences 3.6.1.23dUTP diphosphatase pharmacology the enzyme is a chemotherapeutic target
Show all pathways known for 3.6.1.23Display the word mapDisplay the reaction diagram Show all sequences 3.6.1.23dUTP diphosphatase pharmacology the enzyme is a potential target for antiviral drug design
Show all pathways known for 3.6.1.27Display the word mapDisplay the reaction diagram Show all sequences 3.6.1.27undecaprenyl-diphosphate phosphatase pharmacology the enzyme is an attractive drug target since it is not used by humans
Display the word mapDisplay the reaction diagram Show all sequences 3.6.2.1adenylylsulfatase pharmacology biological sulfation process
Display the word mapDisplay the reaction diagram Show all sequences 3.6.4.B7RadA recombinase pharmacology application potential of archaeal nanobiomotors in drug delivery
Display the word mapDisplay the reaction diagram Show all sequences 3.6.4.13RNA helicase pharmacology conservation of the NTP-binding pocket among viruses of the family Flaviviridae as potential for development of therapeutics
Display the word mapDisplay the reaction diagram Show all sequences 3.6.4.13RNA helicase pharmacology peptide inhibitors reproducing the structure of the autoregulatory motif as possibility to develop effective antivirals
Display the word mapDisplay the reaction diagram Show all sequences 3.6.5.2small monomeric GTPase pharmacology the enzyme is a pharmacological target for the treatment of cardiovascular diseases
Display the word mapDisplay the reaction diagram Show all sequences 3.10.1.1N-sulfoglucosamine sulfohydrolase pharmacology early treatment of CNS lesions by adeno-associated virus-mediated intraventricular injection of both SGSH and SUMF1 genes may represent a feasible therapy for MPS-IIIA
Show all pathways known for 4.1.1.11Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.11aspartate 1-decarboxylase pharmacology Mycobacterium tuberculosis is the etiological agent of tuberculosis and PanD is a potential drug target
Show all pathways known for 4.1.1.15Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.15glutamate decarboxylase pharmacology the enzyme is a potential important marker for the prediction and diagnosis of type 1 diabetes, and for the development of antigen-specific therapies for the treatment of type 1 diabetes
Show all pathways known for 4.1.1.17Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.17ornithine decarboxylase pharmacology the enzyme is a target in the combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor MQT 1426, i.e. D-Lys-spermine, against murine squamous cell carcinoma, overview
Show all pathways known for 4.1.1.17Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.17ornithine decarboxylase pharmacology the enzyme ODC is possibly useful in chemotherapy of human malignancies, such as skin cancer
Show all pathways known for 4.1.1.17Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.17ornithine decarboxylase pharmacology ODC is a target for chemoprevention of apoptosis
Show all pathways known for 4.1.1.17Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.17ornithine decarboxylase pharmacology pharmacological inhibition of ODC is a promising therapeutic paradigm for the treatment of visceral and perhaps other forms of leishmaniasis
Show all pathways known for 4.1.1.23Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.23orotidine-5'-phosphate decarboxylase pharmacology human UMP synthase enzyme may be a potential cancer drug target
Show all pathways known for 4.1.1.25Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.25tyrosine decarboxylase pharmacology biosynthesis of pharmaceutically important monoterpenoid indole alkaloids
Show all pathways known for 4.1.1.28Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.28aromatic-L-amino-acid decarboxylase pharmacology biosynthesis of pharmaceutically important monoterpenoid indole alkaloids
Show all pathways known for 4.1.1.32Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.32phosphoenolpyruvate carboxykinase (GTP) pharmacology development of a PEPCK inhibitor may lead to a new therapeutic strategy for the treatment of type II diabetes
Show all pathways known for 4.1.1.32Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.32phosphoenolpyruvate carboxykinase (GTP) pharmacology orally active compounds reversibly inhibiting PEPCK improve glucose homeostasis in type 2 diabetics
Show all pathways known for 4.1.1.33Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.33diphosphomevalonate decarboxylase pharmacology the enzyme is an antibiotic target, since inhibition prevents the production of isopentenyl diphosphate
Show all pathways known for 4.1.1.50Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.50adenosylmethionine decarboxylase pharmacology the enzyme is a target for cancer chemotherapy
Show all pathways known for 4.1.1.50Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.50adenosylmethionine decarboxylase pharmacology potentially important drug target for the chemotherapy of proliferative and parasitic diseases
Show all pathways known for 4.1.1.50Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.50adenosylmethionine decarboxylase pharmacology potentially important target for chemotherapy of filiarial infection
Show all pathways known for 4.1.1.50Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.50adenosylmethionine decarboxylase pharmacology potential target for therapeutic agents against various parasitic diseases and proliferating disorders
Display the word mapDisplay the reaction diagram Show all sequences 4.1.1.53phenylalanine decarboxylase pharmacology side-effects of pharmacologically active decarboxylation products considered
Display the word mapDisplay the reaction diagram Show all sequences 4.1.2.9phosphoketolase pharmacology polyketide natural products play an important role in the treatment of a wide range of human physiological disorders
Display the word mapDisplay the reaction diagram Show all sequences 4.1.2.10(R)-mandelonitrile lyase pharmacology hydroxynitrile lyases are involved in the synthesis of enantiomerically pure cyanohydrins which are important intermediates in the production of pharmaceuticals and agrochemicals. The enzyme synthesizes (R)-mandelonitrile in both, batch reaction and fed-batch reaction and can be effectively used in the synthesis of (R)-mandelonitrile
Display the word mapDisplay the reaction diagram Show all sequences 4.1.2.10(R)-mandelonitrile lyase pharmacology the enzyme has very high potential for synthesis of cyanohydrins and can be used for the production of enantiopure cyanohydrins. Cyanohydrins are important intermediates in the production of pharmaceuticals and agrochemicals
Show all pathways known for 4.1.2.25Display the word mapDisplay the reaction diagram Show all sequences 4.1.2.25dihydroneopterin aldolase pharmacology the Fas multifunctional enzyme with the activity of the first three enzymes of the folate synthesis pathway: dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase is an attractive target for chemotherapy, sin
Display the word mapDisplay the reaction diagram Show all sequences 4.1.2.42D-threonine aldolase pharmacology efficient, environmentally friendly process for the production of (2R,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-propanoic acid by a recombinant D-threonine aldolase catalyzed aldol addition of glycine and pyridine 4-carboxaldehyde. (2R,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-propanoic acid, is a key intermediate in the synthesis of the (2R,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one, a developmental drug candidate. The aldol addition product directly crystallizes out from the reaction mixture in high purity and high diastereo- and enantioselectivity, contributing to high yield and allowing easy isolation, processing, and downstream utilization
Display the word mapDisplay the reaction diagram Show all sequences 4.1.2.42D-threonine aldolase pharmacology the enzyme has a considerable potential in biocatalysis for the stereospecific synthesis of various beta-hydroxy amino acids, which are valuable building blocks for the production of pharmaceuticals
Display the word mapDisplay the reaction diagram Show all sequences 4.1.2.47(S)-hydroxynitrile lyase pharmacology enantiomerically pure cyanohydrins produced by enzyme-catalyzed synthesis are important synthetic intermediates for pharmaceuticals
Display the word mapDisplay the reaction diagram Show all sequences 4.1.2.48low-specificity L-threonine aldolase pharmacology biotechnological potential for the syntheses of pharmaceutically relevant drug molecules because of the stereospecificity
Show all pathways known for 4.2.1.1Display the word mapDisplay the reaction diagram Show all sequences 4.2.1.1carbonic anhydrase pharmacology extensively investigated enzyme as a target for drug design
Show all pathways known for 4.2.1.46Display the word mapDisplay the reaction diagram Show all sequences 4.2.1.46dTDP-glucose 4,6-dehydratase pharmacology the enzyme is essential to mycobacterial growth and is not found in humans, therefore, it is a potential target for developing new anti-tuberculosis drugs
Display the reaction diagram Show all sequences 4.2.1.50pyrazolylalanine synthase pharmacology production of beta-(pyrazol-1-yl)-L-alanine for pharmacological use by enzyme overexpressed in E. coli
Show all pathways known for 4.2.1.84Display the word mapDisplay the reaction diagram Show all sequences 4.2.1.84nitrile hydratase pharmacology synthesis, biotransformation and biocatalysis of unsaturated/saturated aliphatic, aromatic and heterocyclic nitriles
Display the word mapDisplay the reaction diagram Show all sequences 4.2.2.1hyaluronate lyase pharmacology enzyme is a target for inhibitor design
Display the word mapDisplay the reaction diagram Show all sequences 4.2.2.1hyaluronate lyase pharmacology enzyme can be used for production of pharmaceuticals as an alternative to bovine testicular hyaluronidase, BTH, because the production of BTH is stopped due to risk of BSE
Display the word mapDisplay the reaction diagram Show all sequences 4.2.2.1hyaluronate lyase pharmacology enzyme is a target for development of antimicrobial agents
Display the word mapDisplay the reaction diagram Show all sequences 4.2.2.1hyaluronate lyase pharmacology the enzyme is a target for structure-based design of selective inhibitors as drugs in bacterial infection therapy
Display the word mapDisplay the reaction diagram Show all sequences 4.2.2.1hyaluronate lyase pharmacology in vitro microbial hyaluronate lyase is able to split the hyaluronic acid in atherosclerotic plaques under release of calcium deposits and reduces in vivo the development of atherosclerotic lesions in hyperlipidaemic rabbits
Show all pathways known for 4.2.3.24Display the word mapDisplay the reaction diagram Show all sequences 4.2.3.24amorpha-4,11-diene synthase pharmacology amorpha-4,11-diene is a precursor of artemisinin, an important agent in the treatment of malaria, produced via oxidation
Display the word mapDisplay the reaction diagram Show all sequences 4.2.99.18DNA-(apurinic or apyrimidinic site) lyase pharmacology the enzyme is a potential target in cancer treatment
Show all pathways known for 4.3.1.18Display the word mapDisplay the reaction diagram Show all sequences 4.3.1.18D-Serine ammonia-lyase pharmacology the D-serine dehydratase gene is an excellent marker, especially in the construction of strains for which the use of antibiotic resistance genes as selective markers is not allowed
Show all pathways known for 4.3.1.18Display the word mapDisplay the reaction diagram Show all sequences 4.3.1.18D-Serine ammonia-lyase pharmacology decrease in D-serine content may provide a therapeutic strategy for the treatment of the neurological disorders in which overstimulation of N-methyl-D-aspartate receptors plays a pathological role. D-Serine dehydratase (Dsd1p), which acts dominantly on D-serine, may be a useful D-serine reducing agent. A linear 5-kDa polyethylene glycol (PEG) is conjugated to Dsd1p and the effects of PEG-conjugation on its biochemical and pharmacokinetic properties are examined. PEG-Dsd1p retains activity, specificity, and stability of the enzyme. The PEG modification extended the serum half-life of Dsd1p in mice 6fold, from 3.8 h to 22.4 h. PEG-Dsd1p is much less immunogenic compared to the unmodified enzyme. Intraperitoneal administration of PEG-Dsd1p is effective in decreasing the D-serine content in the mouse hippocampus
Show all pathways known for 4.3.1.24Display the word mapDisplay the reaction diagram Show all sequences 4.3.1.24phenylalanine ammonia-lyase pharmacology the ability of PAL to catalyze the conversion of L-Phe into nontoxic compounds in the absence of additional cofactors leads to its use as a therapeutic agent for the treatment of phenylketonuria
Show all pathways known for 4.3.1.24Display the word mapDisplay the reaction diagram Show all sequences 4.3.1.24phenylalanine ammonia-lyase pharmacology enzyme substitution therapy for the treatment of phenylketonuria
Show all pathways known for 4.3.1.24Display the word mapDisplay the reaction diagram Show all sequences 4.3.1.24phenylalanine ammonia-lyase pharmacology enzyme substitution therapy with the phenylalanine ammonia lyase is a new approach to the treatment of patients with phenylketonuria
Show all pathways known for 4.3.1.24Display the word mapDisplay the reaction diagram Show all sequences 4.3.1.24phenylalanine ammonia-lyase pharmacology the enzyme can reduce the level of L-Phe in the blood and is a prospective drug for the treatment of phenylketonuria
Show all pathways known for 4.3.1.24Display the word mapDisplay the reaction diagram Show all sequences 4.3.1.24phenylalanine ammonia-lyase pharmacology the enzyme is specifically advantageous for the production of the hypertension drug 2-chloro-L-phenylalanine
Show all pathways known for 4.3.1.24Display the word mapDisplay the reaction diagram Show all sequences 4.3.1.24phenylalanine ammonia-lyase pharmacology the shift of the pH-optimum from pH 8.5 for the wild-type enzyme to pH 7.5 with 30% higher specific activity than that of the wild-type enzyme, the prolonged half-life of the mutant enzyme at 70°C, the higher resistance to a low pH of 3.5 and protease make the mutant enzyme E75L a candidate for oral medicine of phenylketonuria
Show all pathways known for 4.3.1.25Display the word mapDisplay the reaction diagram Show all sequences 4.3.1.25phenylalanine/tyrosine ammonia-lyase pharmacology enzyme substitution therapy for the treatment of phenylketonuria
Show all pathways known for 4.3.1.25Display the word mapDisplay the reaction diagram Show all sequences 4.3.1.25phenylalanine/tyrosine ammonia-lyase pharmacology the enzyme is a useful biocatalyst for removal of L-phenylalanine from protein hydrolysates, which can be evaluated as potential ingredients in foodstuffs for phenylketonuria patients. The enzyme is also capable to catalyze the deamination of L-tyrosine to p-coumaric acid but at a substantially low reaction rate. Therefore, the final content of L-Tyr in samples treated with L-phenylalanine ammonia-lyase should be analyzed in each case and taken in consideration to avoid its deficiency in phenylketonuria patients
Show all pathways known for 4.3.2.1Display the word mapDisplay the reaction diagram Show all sequences 4.3.2.1argininosuccinate lyase pharmacology argininosuccinate lyase (ASL) is overexpressed in breast cancer and downregulation of argininosuccinate lyase decreases tumor growth by inhibiting cyclin A2 and NO. Administration of ASL shRNA may be a treatment to prevent cancer cell proliferation and induce cancer cell death
Show all pathways known for 4.3.2.10Display the reaction diagram Show all sequences 4.3.2.10imidazole glycerol-phosphate synthase pharmacology development of allosteric antibiotics, herbicides, and antifungal compounds because the enzyme is absent in mammals but provides an entry point to fundamental biosynthetic pathways in plants, fungi, and bacteria
Show all pathways known for 4.3.2.10Display the reaction diagram Show all sequences 4.3.2.10imidazole glycerol-phosphate synthase pharmacology the enzyme is a potential therapeutic target absent in mammals but present in bacteria, plants, and fungi. Many plant and human pathogens that infect the immunocompromised patient have an IGPS that is highly homologous to the Saccharomyces cerevisiae and Thermotoga maritima enzymes
Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.2strictosidine synthase pharmacology cooverexpression of geraniol-10-hydroxylase and strictosidine synthase improves anti-cancer drug camptothecin accumulation in Ophiorrhiza pumila
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase pharmacology enzyme structure analysis for design of novel therapeutics against bacterial pathogen
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase pharmacology enzyme structure guides design of novel therapeutics
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase pharmacology structure of the enzyme guides the design of novel therapeutics against the methicillin-resistant pathogen
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase pharmacology the enzyme is a promising antibiotic target
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase pharmacology the enzyme is a target for antibiotics
Show all pathways known for 4.3.3.7Display the word mapDisplay the reaction diagram Show all sequences 4.3.3.74-hydroxy-tetrahydrodipicolinate synthase pharmacology the enzyme is an anti-cholera target
Display the word mapDisplay the reaction diagram Show all sequences 4.4.1.4alliin lyase pharmacology allicin contributes to the prevention of stroke and arteriosclerosis. An acid resistant capsule is filled with pellets of alliin and alliinase. In the intestine, alliin and alliinase are dissolved and alicin is liberated
Display the word mapDisplay the reaction diagram Show all sequences 4.4.1.4alliin lyase pharmacology a triggered antimicrobial system based on different sulfoxide substrates and alliinase might be superior to the application of conventional fungicides or allicin itself
Show all pathways known for 4.6.1.1Display the word mapDisplay the reaction diagram Show all sequences 4.6.1.1adenylate cyclase pharmacology activation of cardiac adenylyl cyclase isozyme ACVI expression increases the function of the failing ischemic heart in mice, overview. Increased left ventricular ACVI content also markedly reduces mortality and increases left ventricular function after acute myocardial infarction in mice
Show all pathways known for 4.6.1.1Display the word mapDisplay the reaction diagram Show all sequences 4.6.1.1adenylate cyclase pharmacology pharmacological approaches do not allow cell specific manipulation of cyclic nucleotides in tissue and lack precision in space and time, limitations that can be overcome using the light-activated enzyme
Display the word mapDisplay the reaction diagram Show all sequences 4.6.1.2guanylate cyclase pharmacology activators of sGC may be beneficial in the treatment of a range of diseases including systemic and pulmonary hypertension, heart failure, atherosclerosis, peripheral arterial occlusive disease, thrombosis and renal fibrosis, overview
Display the word mapDisplay the reaction diagram Show all sequences 4.6.1.2guanylate cyclase pharmacology alternative splicing can regulate endogenous ANP/GC-A signaling, thus, angiotensin II-induced alternative splicing of GC-A may represent a mechanism for reducing the sensitivity to atrial natriuretic peptide
Display the word mapDisplay the reaction diagram Show all sequences 4.6.1.2guanylate cyclase pharmacology sGC is a target for therapeutic intervention in pulmonary arterial hypertension
Display the word mapDisplay the reaction diagram Show all sequences 4.6.1.2guanylate cyclase pharmacology pharmacological approaches do not allow cell specific manipulation of cyclic nucleotides in tissue and lack precision in space and time, limitations that can be overcome using the light-activated enzyme
Display the word mapDisplay the reaction diagram Show all sequences 4.6.1.18pancreatic ribonuclease pharmacology radical-scavenging effects of the ribonuclease inhibitor CPRI may contribute to its function in the cell protection from peroxidative injuries unrelated to inhibition of RNases
Display the word mapDisplay the reaction diagram Show all sequences 4.6.1.18pancreatic ribonuclease pharmacology inhibitors can be the starting point for the development of compounds that can be used as pharmaceuticals against pathologies associated with ribonuclease A homologues such as human angiogenin, which is implicated in tumor induced neovascularization
<< < Results 501 - 600 of 662 > >>